SCHEMBL5050768

SCHEMBL5050768

CC(C)(Cc1cc(C(=O)/C=C/c2ccc(C(=O)O)cc2)cc2c1C(C)(C)CCC2(C)C)c1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.47
CYP3A4 P08684 2/20 0.47
BLM P54132 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HSD17B10 Q99714 2/20 0.47
MAPT P10636 1/20 0.47
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.47
CASP7 P55210 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
RARA P10276 8/20 0.44
RARB P10826 8/20 0.44
RARG P13631 8/20 0.44
CYP1A1 P04798 1/20 0.43
CYP1B1 Q16678 1/20 0.43
CYP26A1 O43174 2/20 0.41
RXRA P19793 5/20 0.41
RXRB P28702 2/20 0.41
TNFRSF1A P19438 1/20 0.41
NFKB1 P19838 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5050773 1.00 TP53 (0.47) TP53CYP3A4BLMSMN1; SMN2HSD17B10
SCHEMBL5050750 0.92 MAPT (0.47) TP53CYP3A4BLMSMN1; SMN2HSD17B10
SCHEMBL5050748 0.92 MAPT (0.47) TP53CYP3A4BLMSMN1; SMN2HSD17B10
SCHEMBL5049651 0.89 MAPT (0.45) TP53CYP3A4BLMSMN1; SMN2HSD17B10
SCHEMBL5049653 0.89 MAPT (0.45) TP53CYP3A4BLMSMN1; SMN2HSD17B10
SCHEMBL5047093 0.85 RARA (0.48) TP53CYP3A4BLMSMN1; SMN2HSD17B10
SCHEMBL5047091 0.85 RARA (0.48) TP53CYP3A4BLMSMN1; SMN2HSD17B10
SCHEMBL5043980 0.84 RARB (0.56) TP53CYP3A4BLMSMN1; SMN2HSD17B10
SCHEMBL5043981 0.84 RARB (0.56) TP53CYP3A4BLMSMN1; SMN2HSD17B10
SCHEMBL5043977 0.84 RARB (0.56) TP53CYP3A4BLMSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US claimed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US claimed
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US disclosed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG TP53 369/4885CYP3A4 2257/4885BLM 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.